Virpax Pharmaceuticals, Inc. financial data

Symbol
VRPX on Nasdaq
Location
1055 Westlakes Drive, Suite 300, Berwyn, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 79.1 % -80.5%
Debt-to-equity -479 % -1564%
Return On Equity -78.3 % -23%
Return On Assets -338 % -317%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.89M shares
Common Stock, Shares, Outstanding 4.89M shares -58.3%
Entity Public Float 9.4M USD -35.7%
Common Stock, Value, Issued 49 USD -58.1%
Weighted Average Number of Shares Outstanding, Basic 4.66M shares +298%
Weighted Average Number of Shares Outstanding, Diluted 4.66M shares +298%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.81M USD +7.97%
General and Administrative Expense 7.56M USD -13.4%
Operating Income (Loss) -13.4M USD +5.24%
Nonoperating Income (Expense) 8.13K USD -93.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -16.9M USD +6.35%
Net Income (Loss) Attributable to Parent -13.2M USD +2.76%
Earnings Per Share, Basic -8.82 USD/shares +66.1%
Earnings Per Share, Diluted -8.82 USD/shares +66.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 304K USD -97.7%
Assets 304K USD -97.7%
Liabilities, Current 2.36M USD -63.9%
Liabilities 2.36M USD -63.9%
Retained Earnings (Accumulated Deficit) -68.2M USD -24.1%
Stockholders' Equity Attributable to Parent -2.05M USD -132%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 19.4M USD -53.1%
Liabilities and Equity 304K USD -97.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.73M USD -285%
Net Cash Provided by (Used in) Financing Activities 454K USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 4.89M shares -58.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.87M USD -87.4%
Deferred Tax Assets, Valuation Allowance 15.9M USD +19.6%
Deferred Tax Assets, Gross 15.9M USD +19.6%
Deferred Tax Assets, Operating Loss Carryforwards 8.85M USD +7.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 66.2M USD +7.61%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 6.62M USD +91.4%
Share-based Payment Arrangement, Expense 118K USD -83%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%